Skip to main content
. Author manuscript; available in PMC: 2014 Dec 30.
Published in final edited form as: J Clin Psychopharmacol. 2015 Feb;35(1):34–42. doi: 10.1097/JCP.0000000000000246

Figure 1.

Figure 1

Ethanol consumption for subjects in the levetiracetam (LEV), placebo (PLC), topiramate (TOP), and zonisamide (ZON) groups. Mean (SE) weekly values are presented for drinks per day (top) and percent days heavy drinking (bottom) obtained during the prescreening (Week 0), titration (weeks 1-7), and maintenance phases of the study (weeks 8-12).